TrioxBio Israeli Company

TrioxBio develops and commercializes proprietary synthetic small molecules to treat pathologic states caused by the overproduction of nitric oxide. The company's API, S-ethylisothiouronium diethylphosphate, MTR-104, is a nitric oxide synthase (NOS) inhibitor that blocks the production of nitric oxide, preventing the dilation of blood vessels and other detrimental effects caused by excessive NOS activity.